Developing individualized cancer treatments

Leveraging advanced technology synergies

Becoming a leader in cancer immunotherapy

BioNTech – Medicines as Unique as You

BioNTech combines the scientific understanding of each cancer with the most advanced technologies to provide the best therapies to treat cancer patients individually.

BioNTech in the News

BioNTech Raises USD 325 Million in an Upsized Series B Financing to Further Advance Individualized Immuno-Oncology Pipeline

9th July 2019

BioNTech and Genmab Initiate First-In-Human Phase I/IIa Trial of Bispecific Antibody DuoBody®-PD-L1x4-1BB in Solid Tumors

17th June 2019

BioNTech Acquires MabVax Therapeutics’ Antibody Assets to Expand Portfolio

8th May 2019

BioNTech Congratulates CEO and Co-founder Prof. Ugur Sahin on German Cancer Award 2019

28th February 2019

BioNTech to Acquire Antibody Generation Unit of MAB Discovery

23rd January 2019

BioNTech Announces Corporate Form Transition from AG to SE

4th January 2019

Sanofi Invests EUR 80m in BioNTech as Partners Extend Collaboration

4th January 2019

BioNTech and the University of Pennsylvania Enter into Strategic Research Collaboration

5th November 2018

BioNTech Signs Collaboration Agreement with Pfizer to Develop mRNA-based Vaccines for Prevention of Influenza

16th August 2018

BioNTech and Genevant Sciences Sign Strategic mRNA-Focused Partnership in Rare Diseases

10th July 2018

BioNTech Appoints Dr. Özlem Türeci as Chief Medical Officer

29th May 2018

BioNTech Secures USD 270 Million in Series A Financing

4th January 2018

BioNTech to Present at 36th Annual J.P. Morgan Healthcare Conference

21st December 2017

BioNTech Honored as WuXi AppTec Biotech Company of the Year at Scrip Awards 2017

30th November 2017

Research & Technology

BioNTech combines its ground-breaking research with rapidly evolving technologies to develop pioneering therapeutics for cancer and beyond.

Partnering

BioNTech’s commercial strategy is to collaborate with selected partners that share our vision and commitment to develop and commercialize truly innovative and disruptive immunotherapies.

Pipeline

BioNTech develops and commercializes a broad product pipeline using different scientific approaches and cutting-edge technology platforms. BioNTech´s clinical pipeline represents a number of industry firsts.